Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 07 - 06 save search
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
Published: 2021-07-06 (Crawled : 21:00) - globenewswire.com
NXTC | $1.6 0.0% 100K
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.65%
solid tumors phase 1 trial phase 2 phase 3
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
Published: 2021-07-06 (Crawled : 20:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 20.43%
H: 26.49%
C: 1.19%
collaboration phase 3 keytruda
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update
Published: 2021-07-06 (Crawled : 17:00) - biospace.com/
ASND | $142.14 1.41% 1.39% 250K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: -1.57%
phase 3 trial enroll
Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients
Published: 2021-07-06 (Crawled : 17:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -0.36%
H: 6.67%
C: 4.52%
covid biopharma phase 3
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
Published: 2021-07-06 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.895 -1.81% -1.85% 2.5M
|
Health Technology
|
| O: 7.76%
H: 1.17%
C: -2.93%
phase 3 trial enroll
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 18.57%
H: 12.89%
C: 3.49%
fda phase 3 trial macular
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.